CLYM vs SGMO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CLYM Captures Institutional Edge (2โ2 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical while SGMO counters with relative strength in Valuation, Options & Structure. Fundamentally, CLYM trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus SGMO at 0.4x Forward P/E and -175.5% operating margin (+88.4% YoY). In options structure, CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SGMO sits in UNCLASSIFIED (71st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CLYM | SGMO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $638.5M | $55.9M | Larger Scale | CLYM |
| Trailing P/E Ratio Valuation | N/M | 0.4x | Lower Multiple | SGMO |
| Forward P/E Ratio Valuation | N/M | 0.4x | Lower Multiple | SGMO |
| Revenue Growth (YoY) Growth | +0.0% | +88.4% | Higher Growth | SGMO |
| Operating Margin (TTM) Profitability | 0.0% | -175.5% | Higher Margin | CLYM |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -29.3% | -2891.8% | Higher ROE | CLYM |
| 52-Week Range Position Momentum | 50% ($2โ$18) | 9% ($0โ$1) | Stronger Trend | CLYM |
| Beta / 30D Volatility Risk Regime | 1.51ฮฒ ยท 114% Vol | 1.49ฮฒ ยท 206% Vol | Lower Realized Risk | CLYM |
| Unified Institutional Score Composite Signal | 41.9 / 100 (SELL) | 52.0 / 100 (HOLD) | Higher Composite | SGMO |